Indeed, the use of drugs such as aryl hydrocarbon receptor antagonist (StemRegenin, SR1) or 16,16‐dimethyl‐prostaglandin E2 (dmPGE2) capable of improving the engraftment of gene‐edited HSCs in transplanted recipients (Genovese et al, 2014), or molecules capable of enhancing the efficacy of HDR (Zhang et al, 2016) may further aid in the development of therapeutic gene editing for the treatment of inherited diseases affecting the hematopoietic system, including FA. Here, AHR is linked to hereditary disease.